Luma Group closed its inaugural life sciences venture fund at $410 million, saying it will deploy capital across therapeutics, devices, diagnostics and digital health across the US, Europe and Israel. The final close positions the firm to back companies from Series A through growth-stage development. Separately, Encoded Therapeutics secured a $275 million Series F led by GV and another undisclosed healthcare investor to support its Dravet syndrome program and scale internal genetic medicine manufacturing. Both moves point to sustained investor willingness to fund platform buildout and late discovery execution.